Fortunately, the new wave of weight loss drugs including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may help some women with unwanted menopause weight gain
Optical coherence tomography Change in pRNFL thickness was not associated with the treatment group but with pRNFL thickness at baseline (M3: \(\beta\)= 0.32, 95% CI 0.41, 0.23
Not for use in humans, animals, or any clinical or therapeutic context
At its core, semaglutide is a GLP-1 receptor agonist, which means it works by mimicking the functions of the naturally occurring hormone GLP-1 in your body
Gastrointestinal changes some users report altered appetite or mild stomach upset, particularly with oral forms
Fun fact: About 80% of users report their stomach issues improve dramatically by week 6-8